CDKN2A and lung carcinoma: The inverse relationship between Prame and p14/ARF was observed in 4/6 of paired breast cancer tissues (P1–P4, 66%) and 2/3 of lung cancer tissues (P5, P6, 66%) (Fig. 5I), which further confirmed the role of Prame in mediating p14/ARF degradation.